Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA), which has announced a transition to the name LeonaBio, Inc. with a new ticker "LONA," regularly issues news updates as a clinical-stage biopharmaceutical company headquartered in the Seattle, Washington area. Its press releases focus on the development of novel small molecule therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
News for ATHA commonly covers progress in the company’s lead programs, lasofoxifene and ATH-1105. Updates include clinical trial milestones such as completion of a first-in-human Phase 1 trial of ATH-1105 in healthy volunteers, presentations of safety, tolerability and pharmacokinetic data, and enrollment status for the Phase 3 ELAINE-3 trial of lasofoxifene in ER+, HER2-negative, ESR1-mutated metastatic breast cancer. The company also reports on preclinical findings for ATH-1105 in ALS models and scientific presentations at major neurology and ALS-focused conferences.
Investors following ATHA news will also see corporate and regulatory developments, including announcements about a 10-for-1 reverse stock split aimed at maintaining Nasdaq listing requirements, notices of regained compliance with the minimum bid price rule, and details of private placement financings intended to support clinical and regulatory milestones. Additional releases describe Athira’s strategic alternatives review and its licensing agreements with Sermonix Pharmaceuticals and Ligand Pharmaceuticals for lasofoxifene.
This news feed provides a centralized view of Athira/LeonaBio’s clinical, scientific and corporate disclosures, allowing readers to track how its oncology and neurology pipelines evolve over time and how financing and licensing arrangements relate to ongoing and planned trials.
Athira Pharma, Inc. (NASDAQ: ATHA) reported its financial results for the year ending December 31, 2022. The company is advancing its Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease, aiming for enrollment completion by mid-2023 and topline data in early 2024. Athira also progresses with ATH-1105 for ALS and maintains a robust balance sheet with $245.2 million in cash, down from $319.7 million in 2021. The net loss for 2022 was $95.6 million, or $2.53 per share, compared to a loss of $54.9 million, or $1.49 per share, in 2021. Increased operational costs were noted in R&D and G&A expenses.
Athira Pharma (NASDAQ: ATHA) is set to showcase its innovative small molecule therapeutics aimed at enhancing the HGF/MET system for treating various neurodegenerative diseases.
On March 15, 2023, Athira's management will participate in the Needham Neurosciences Investor Forum, followed by the Stifel 2023 CNS Days on March 28-29, 2023. Investors can access live webcasts of the presentations on Athira's website.
Focused on restoring neuronal health, Athira is advancing treatments for Alzheimer's and Parkinson's diseases, among others. The company emphasizes its commitment to developing effective therapies.
Athira Pharma, a late clinical-stage biopharmaceutical company, will present at two scientific conferences: ASENT 2023 from March 13-15 and AD/PD 2023 from March 28-April 1. The presentations will showcase preclinical data on enhancing the HGF/MET pathway for neurodegenerative diseases. Key presentations include oral and poster sessions focused on ATH-1105, ATH-1020, and Fosgonimeton, highlighting their neuroprotective properties in models of ALS, diabetic neuropathic pain, Alzheimer's, and Parkinson's diseases. These engagements aim to demonstrate the therapeutic potential of Athira's product candidates, emphasizing their innovative approach to restoring neuronal health.
Athira Pharma (NASDAQ: ATHA) recently released a review paper emphasizing the urgent need for innovative treatments for Alzheimer’s disease, specifically highlighting the potential of fosgonimeton, a small molecule modulator of the HGF/MET system. Published in the Journal of Alzheimer’s Disease, the article discusses current drug development limitations and the necessity for novel research methodologies. Athira's clinical candidate is currently being evaluated in the Phase 2/3 LIFT-AD study, targeting mild-to-moderate Alzheimer’s disease, with enrollment expected to conclude by mid-2023 and topline results anticipated in early 2024.
Athira Pharma, Inc. (NASDAQ: ATHA) has promoted Kevin Church, Ph.D., to Chief Scientific Officer, recognizing his vital role in advancing the company’s research on neurodegenerative diseases. Dr. Church, who has been with Athira since 2016, previously served as Executive Vice President of Research and has been instrumental in exploring the HGF/MET pathway for potential therapies targeting Alzheimer's, Parkinson's, and other neurological disorders. His leadership is expected to strengthen the company’s innovative approach to restoring neuronal health.
Athira Pharma (NASDAQ: ATHA) provided a pipeline update, highlighting its ongoing Phase 2/3 LIFT-AD study for mild-to-moderate Alzheimer’s disease with expected topline data in early 2024. The study aims to investigate the candidate fosgonimeton for neuroprotective effects. Additionally, ATH-1105, targeting amyotrophic lateral sclerosis (ALS), is set for an IND filing in 2023. Athira reported a solid financial position with $260 million in cash as of September 30, 2022, reinforcing its capability to advance its development programs.
Athira Pharma (NASDAQ: ATHA) published preclinical data on December 20, 2022, highlighting the neuroprotective and cognitive-enhancing effects of fosgonimeton (ATH-1017). This research demonstrates fosgonimeton's potential in enhancing the HGF/MET neurotrophic system, crucial for addressing dementia and neurodegenerative diseases. The study shows that fosgonimeton promotes neuronal protection and cognitive improvement in various animal models affected by neurodegeneration. These findings support ongoing clinical development efforts targeting diseases like Alzheimer's and Parkinson's.
Athira Pharma (NASDAQ: ATHA) presented findings on ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, at the 33rd International Symposium on ALS/MND. In a TDP-43 mouse model of ALS, ATH-1105 demonstrated significant improvements in motor function, nerve function, and reductions in neurodegeneration markers. Treated mice showed better weight retention, enhanced motor skills, and reduced inflammation biomarkers. These results support ATH-1105 as a potential therapeutic candidate for ALS and possibly other neurodegenerative diseases.
Athira Pharma (NASDAQ: ATHA) announced a virtual R&D event titled “Enhancing the HGF/MET System to Fight Neurodegenerative Diseases,” scheduled for December 7, 2022, from 2:00 p.m. to 3:30 p.m. EST. The event will showcase preclinical and clinical data supporting the potential of HGF/MET in treating neurodegenerative diseases. Key executives, including Mark Litton, will present updates on Athira’s therapeutic pipeline, followed by an interactive Q&A session. Interested participants can pre-register and access the live webcast on Athira's website.
Athira Pharma (NASDAQ: ATHA) presented new biomarker data from the completed ACT-AD Phase 2 study of fosgonimeton, showing significant reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) that correlate with improved clinical outcomes in mild-to-moderate Alzheimer’s patients. Fosgonimeton treatment also demonstrated directional improvements in Alzheimer’s protein pathologies compared to placebo. The company continues to progress in its Phase 2/3 LIFT-AD study, aiming for topline data release in early 2024.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
